ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

TARS Tarsus Pharmaceuticals Inc

37.03
0.18 (0.49%)
07 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Tarsus Pharmaceuticals Inc NASDAQ:TARS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.18 0.49% 37.03 34.71 37.00 37.85 36.35 37.00 679,559 01:00:00

Tarsus to Present at Bank of America 2022 Healthcare Conference

06/05/2022 2:00pm

GlobeNewswire Inc.


Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Tarsus Pharmaceuticals Charts.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus, will present a corporate update at the Bank of America 2022 Healthcare Conference on Wednesday, May 11, 2022 at 12:00pm PT / 3:00pm ET.

A live webcast and additional information about the presentation can be accessed on the events section of the Tarsus website at www.tarsusrx.com. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Tarsus is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic which has demonstrated positive results in two pivotal trials for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. In addition, Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial.

Contacts: Media Contact:Adrienne KempSr. Director, Corporate Communications(949) 922-0801AKemp@tarsusrx.com

Investor Contact:David NakasoneHead of Investor Relations(949) 620-3223DNakasone@tarsusrx.com

1 Year Tarsus Pharmaceuticals Chart

1 Year Tarsus Pharmaceuticals Chart

1 Month Tarsus Pharmaceuticals Chart

1 Month Tarsus Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock